Chronic Obstructive Pulmonary Disease Drug Market- Global Growth, Trends and Forecast (2022 - 2029) By Drug Class, By Distribution Channel and By Regions

Who are the Major Players in Chronic Obstructive Pulmonary Disease Drug Market?

Market Growth Reports lists out all the Chronic Obstructive Pulmonary Disease Drug Market companies that are presently striving to reduce the impact of Covid-19 pandemic on the Market- AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.), CHIESI Farmaceutici S.p.A., Orion Corporation, Mylan N.V., Others.

Industry News:

CHIESI Farmaceutici S.p.A. entered into an exclusive global license agreement

In January 2019, TiumBio, a clinical-stage private biotech business established in South Korea, has signed an exclusive global licencing deal with CHIESI Farmaceutici S.p.A. TiumBio focuses on the development of novel therapeutics for uncommon illnesses. This collaboration aims to create novel compounds for the treatment of respiratory disorders.

What are the major Drug Class and Distribution Channel for Chronic Obstructive Pulmonary Disease Drug Market?

By Drug Class, it is segmented into

• Combination Therapy

• Triple Therapy
• Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
• Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)

• Others

• Corticosteroids
• Phosphodiesterase Type 4 Inhibitors
• Mucokinetics
• Bronchodilators
  • Long Acting Beta Agonist (LABA)
  • Short Acting Beta Agonist (SABA)
  • Long Acting Muscarinic Antagonist (LAMA)
• Others

By Distribution Channel is segmented into

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Chronic Obstructive Pulmonary Disease Drug Market Regional Analysis

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa make up the worldwide COPD medications market. Because of exponentially expanding air pollution, fast industrialisation, and the adoption of a sedentary lifestyle, North America is expected to dominate the worldwide COPD medications market. Furthermore, rising smoking rates and a lack of understanding of COPD are projected to increase the disease's prevalence, leading in greater use of COPD medications. COPD is frequent in both men and women, according to The Lung Association, and is the sixth most common cause of hospitalization in women and the fourth most common in men in Canada.

Because of the increased frequency of respiratory distress diseases in Asia Pacific, the Middle East, and Africa, the worldwide COPD medicine market has a lot of room to develop. According to WHO data, over 90% of COPD-related deaths occur in poor and middle-income countries. Rapid urbanization, which increases air pollution, increases the risk of developing respiratory disorders like COPD, resulting in lucrative potential possibilities for the COPD medications market in these countries.

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World
  • Middle East & Africa
  • Latin America

1. INTRODUCTION
   1. MARKET DEFINITION
   2. MARKET DYNAMICS
   3. MARKET SEGMENTATION
   4. REPORT TIMELINES
   5. KEY STAKEHOLDERS
2. RESEARCH METHODOLOGY
   1. DATA MINING
      1. SECONDARY RESEARCH
      2. PRIMARY RESEARCH
      3. SUBJECT MATTER EXPERT ADVICE
   2. QUALITY CHECK
   3. FINAL REVIEW
      1. DATA TRIANGULATION
      2. BOTTOM-UP APPROACH
      3. TOP-DOWN APPROACH
      4. RESEARCH FLOW
3. EXECUTIVE SUMMARY
   1. INTRODUCTION
   2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET BY DRUG CLASS
   3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET BY CHANNEL DISTRIBUTION
4. MARKET DYNAMICS
   1. DRIVERS
      1. INCREASING DEMAND FOR MSM SUPPLEMENT
   2. RESTRAINTS
      1. STRINGENT ENVIRONMENTAL REGULATIONS
      2. HIGH COST ON MATERIALS
   3. OPPORTUNITIES
      1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS GROWTH
   4. APPLICATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS IMPACT OF COVID 19
5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET, BY DRUG CLASS
   1. INTRODUCTION
   2. COMBINATION THERAPY
      1. LONG-ACTING MUSCARINIC ANTAGONIST AND INHALED CORTICOSTEROIDS (LAMA-ICS)
      2. LONG ACTING BETA-AGONIST AND INHALED CORTICOSTEROIDS (LABA-ICS)
      3. TRIPLE THERAPY
      4. OTHERS
6. CORTICOSTEROIDS
7. PHOSPHODIESTERASE TYPE 4 INHIBITORS
8. MUCOKINETICS
9. BRONCHODILATORS
   1. LONG-ACTING BETA AGONIST (LABA)
   2. SHORT-ACTING BETA AGONIST (SABA)
   3. LONG-ACTING MUSCARINIC ANTAGONIST
10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL
    1. INTRODUCTION
    2. HOSPITAL PHARMACIES
    3. RETAIL PHARMACIES
    4. ONLINE PHARMACIES
11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE DRUGS MARKET, BY REGION
    1. NORTH AMERICA
       1. US
       2. CANADA
       3. MEXICO
    2. EUROPE
       1. GERMANY
       2. FRANCE
       3. UK
       4. ITALY
       5. RUSSIA
       6. REST OF EUROPE
    3. APAC
       1. CHINA
       2. SOUTH KOREA
       3. JAPAN
       4. INDIA
       5. AUSTRALIA
       6. ASEAN
       7. REST OF APAC
    4. MIDDLE EAST AND AFRICA
       1. SAUDI ARABIA
       2. UAE
       3. SOUTH AFRICA
       4. TURKEY
       5. REST OF MEA
    5. SOUTH AMERICA
       1. BRAZIL
       2. REST OF MEA
       3. ARGENTINA
       4. REST OF SOUTH AMERICA
12. COMPETITIVE LANDSCAPE
    1. MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    2. AND AGREEMENTS
       1. KEY DEVELOPMENT
    3. MARKET SHARE PERCENT/ RANKING ANALYSIS
    4. STRATEGIES ADOPTED BY LEADING PLAYERS
13. COMPANY PROFILES
    1. BUSINESS OVERVIEW
    2. COMPANY SNAPSHOT
    3. PRODUCT BENCHMARKING
    4. STRATEGIC INITIATIVES
       1. ASTRAZENECA
       2. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
       3. GLAXOSMITHKLINE PLC
       4. NOVARTIS AG
       5. TEVA PHARMACEUTICAL INDUSTRIES LTD.
       6. SUNOVION PHARMACEUTICALS INC. (SUMITOMO DAINIPPON PHARMA CO., LTD.)
       7. CHIESI FARMACEUTICI S.P.A.
       8. ORION CORPORATION
       9. MYLAN N.V.

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.